Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ABCL · NASDAQ · Pharmaceutical Preparations
Abcellera Biologics (ABCL) · oqro.io/stocks/ABCL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$11.49−0.13 (−1.12%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Including 1 routine filing (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider buying
First buy since 2023Traded Nov 13 · filed the same day
The CFO of Abcellera Biologics paid $97K out of pocket for Abcellera Biologics shares. 1 other person at Abcellera Biologics bought some too, in the same month. It was the first purchase in over a year.
Insider filing
Traded Nov 13 · filed the same day
Gift or transfer — classified separately from trades.
Insider buying
First insider buy since Mar 2025Traded Nov 12 · filed the same day
Since the trade −1.1% · S&P 500 −0.4% · to Nov 13
A major shareholder of Abcellera Biologics paid $699K out of pocket for Abcellera Biologics shares. 1 other person at Abcellera Biologics bought some too, in the same month. It was the first purchase in 20 months.
Insider buying
Traded Mar 11, 2025 · filed the same day
A major shareholder of Abcellera Biologics paid $742K out of pocket for Abcellera Biologics shares. 1 other person at Abcellera Biologics bought some too, in the same month.
Insider buying
Traded Mar 10, 2025 · filed the same day
An Abcellera Biologics director paid $58K out of pocket for Abcellera Biologics shares. 1 other person at Abcellera Biologics bought some too, in the same month. Shares held went up 17% with this purchase.
Insider buying
Traded Mar 6, 2025 · filed 1 day later
An Abcellera Biologics director paid $141K out of pocket for Abcellera Biologics shares. 1 other person at Abcellera Biologics bought some too, in the same month. Shares held went up 70% with this purchase.
2 open-market purchases and 0 open-market sales by insiders of ABCL between Jan 25, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 9, 2026. The data provider lists the next release for Feb 22, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 9, 2026 | None | None | 2 purchases |
| Aug 5, 2026 | None | None | None |
| May 11, 2026 | None | None | None |
| Feb 24, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
